Sunstone Life Science Ventures

Type

Venture Capital

Status

Active

Location

Copenhagen, Denmark

Total investments

61

Average round size

26M

Portfolio companies

34

Rounds per year

3.59

Lead investments

5

Follow on index

0.44

Exits

11

Stages of investment
SeedEarly Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsWellnessGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeutics

Summary

The leading representative office of defined VC is situated in the Copenhagen. The fund was located in Europe if to be more exact in Denmark.

Among the various public portfolio startups of the fund, we may underline F2G, Anergis, OxThera Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Denmark. Among the most successful fund investment fields, there are Electronics, Medical. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 3 of the founder, the chance for it to get the investment is meager.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. Comparing to the other companies, this Sunstone Life Science Ventures performs on 2 percentage points less the average number of lead investments. The increased amount of exits for fund were in 2014.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Sunstone Life Science Ventures, startups are often financed by Novo Seeds, Novo Holdings, Novartis Venture Fund. The meaningful sponsors for the fund in investment in the same round are Novo Holdings, Forbion Capital Partners, Omega Funds. In the next rounds fund is usually obtained by Novo Holdings, Atlas Venture, Aescap Venture.

The overall number of key employees were 6.

Show more

Investor highlights

Industry focus
Biotech/Life Sciences
Stage focus
Series ASeries B
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 37 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
EUR 92000000
Fund raised date
2019-01-01

Analytics

Total investments
61
Lead investments
5
Exits
11
Rounds per year
3.59
Follow on index
0.44
Investments by industry
  • Biotechnology (49)
  • Health Care (41)
  • Medical (30)
  • Therapeutics (19)
  • Pharmaceutical (14)
  • Show 23 more
Investments by region
  • Denmark (27)
  • United Kingdom (3)
  • Switzerland (8)
  • Germany (5)
  • France (2)
  • Show 6 more
Peak activity year
2016
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
58M
Group Appearance index
0.97
Avg. company exit year
9
Avg. multiplicator
9.92
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Anergis 04 Apr 2016 Biotechnology, Health Care, Medical, Personal Health, Life Science Late Stage Venture 5M Switzerland, Vaud
Resalis Therapeutics 04 Jan 2024 Early Stage Venture 11M Piemonte, Torino, Italy

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.